CIK 0001626971
- Non-accelerated filer
- Smaller reporting company
Corvus Pharmaceuticals, Inc.
Sign in to watch- Ticker
- CRVS
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- Operating
- EIN
- 464670809
- Phone
- +1 650-900-4520
- Business address
- 901 GATEWAY BLVD, THIRD FLOOR, SOUTH SAN FRANCISCO, CA, 94080
- 4 Open-market buy Director bought 4,716 shares at $13.09 ($61,732)
- 4 Open-market buy Director bought 6,800 shares at an average $11.77 ($80,035)
- 4 Open-market buy Director bought 6,800 shares at an average $11.77 ($80,035)
- 4 Open-market buy President and CEO bought 30,300 shares at an average $10.00 ($302,981)
- 4 Open-market buy 10% owner bought 70,000 shares at $10.00 ($700,000)
- 4 Open-market buy 10% owner bought 666,666 shares at $15.00 ($9,999,990)
- 4 Open-market buy Director bought 550,000 shares at $15.00 ($8,250,000)
- 4 Open-market buy Director bought 550,000 shares at $15.00 ($8,250,000)
- 4 Open-market buy 10% owner bought 200,000 shares at $15.00 ($3,000,000)
- 4 Conversion President and CEO acquired 328,765 shares (conversion)
- 4 Conversion Chief Financial Officer acquired 42,608 shares (conversion)
- 4 Open-market buy Director bought 200,000 shares at $15.00 ($3,000,000)
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
Page 12 of 13 · 252 filings